The trial was registered at ClinicalTrials.gov (registration: NCT05073835), the UK Medicines and Healthcare products Regulatory Agency and the European Union Drug Regulating Authority Clinical Trials (EudraCT no
After Your Treatment Unlike surgical weight loss treatments, semaglutide does not require any recovery or downtime
Despite my warnings, she decided to stop taking the medication to save money
Reducing visceral fat is often less about quick fixes and more about improving the underlying metabolic environment of the body

Patient Selection and Assessment Criteria for patient eligibility, medical history and contraindications According to the package insert: Wegovy (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management: YES: adults with an initial body mass index (BMI) of 30 kg/m2 (obesity) or 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity) NO: Patients with a personal or family history of MTC Patients with MEN 2 Patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in semaglutide WARNING & PRECAUTIONS: Risk of the following: Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Hypoglycemia Acute Kidney Injury Hypersensitivity Reactions Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Heart Rate Increase Suicidal Behavior and Ideation ADDITIONAL Patients should be warned about the following: History of type 1 diabetes or diabetic ketoacidosis, as semaglutide is not indicated for these conditions

Maryland Trim Clinic (MTC) in Laurel, MD can support people who are trying to make informed decisions about medical weight management, GLP-1 treatment, nutrition, body composition, and long-term maintenance